Serum Proteome Profiling Identifies Early Markers of Therapeutic Response to Neoadjuvant Chemotherapy of Breast Cancer
We performed a proteomic serum profiling of patients with non-metastasized breast cancer (BC) who received neoadjuvant chemotherapy (NACT). Samples were collected at three timepoints during NACT. Furthermore, we compared serum samples of BC patients pre-NACT to a control group of healthy volunteers.
- 12/05/2023
- 84 samples
- DAC: EGAC00001002656
- Technology: Qexactive Plus
Access to Proteomic profiling of human serum from breast cancer patients spectral files.
The recipient of files agrees to fully consent to the Data Access Agreement (DAA) provided by the Institute of Surgical Pathology for data access of the Proteomics' serum sample files of breast cancer patients, which is based on the harmonized DAA as provided by the EGA.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |